Oncotarget

Meta-Analysis:

GSTP1 polymorphism predicts treatment outcome and toxicities for breast cancer

Jie Ma, Shao-Liang Zhu, Yang Liu, Xiang-Yang Huang and Dan-Ke Su _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:72939-72949. https://doi.org/10.18632/oncotarget.18513

Metrics: PDF 1793 views  |   HTML 2056 views  |   ?  


Abstract

Jie Ma1,*, Shao-Liang Zhu2,*, Yang Liu3,*, Xiang-Yang Huang1 and Dan-Ke Su1

1Department of Radiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China

2Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China

3Department of Radiotherapy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China

*These authors contributed equally to this work

Correspondence to:

Dan-Ke Su, email: [email protected]

Keywords: GSTP1, breast cancer, treatment outcome, toxicities, meta-analysis

Received: October 07, 2016     Accepted: May 23, 2017     Published: June 16, 2017

ABSTRACT

This study aimed to investigate the association of the GSTP1 gene polymorphism with the outcomes and toxicities of treatments in breast cancer. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for the association of GSTP1 polymorphism with tumour response and toxicities, and the hazard ratios (HRs) and 95% CIs were calculated for the association between GSTP1 polymorphism and overall survival (OS). The statistical analysis showed that the GSTP1 polymorphism was not associated with tumour response or OS. A significant increase in the incidence of toxicities was observed (GA vs. AA OR = 1.45, 95% CI = 1.04–2.01, P = 0.028; GG vs. AA OR = 1.47, 95% CI = 1.03–2.10, P = 0.036; recessive model OR = 1.54, 95% CI = 1.13–2.09, P = 0.006; and allele model OR = 1.35, 95% CI = 1.07–1.71, P = 0.011), especially in the chemotherapy ± surgery group (GA vs. AA OR = 1.64, 95% CI = 1.05–2.56, P = 0.030; recessive model OR = 1.72, 95% CI = 1.17–2.54, P = 0.006; and allele model OR = 1.57, 95% CI = 1.11–2.21, P = 0.010). Our results indicate that the GSTP1 polymorphism may be associated with increased toxicity, especially in patients treated with chemotherapy ± surgery.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18513